

2019 novel Coronavirus

**Global research and innovation forum:
towards a research roadmap**

Preliminary AGENDA

11-12 February 2020

WHO Headquarters, Geneva, Switzerland

Executive Board room

Version 6.0, 7 February, 2020



Background

The [WHO R&D Blueprint](#) is a global strategy and preparedness plan that allows the rapid activation of R&D activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crisis.

The global imperative for research is to maintain a high-level discussion platform which enables consensus on strategic directions, nurtures scientific collaborations and, supports optimal and rapid research to address crucial gaps, without duplication of efforts.

Understanding the disease, its reservoirs, its transmission, its clinical severity and developing effective counter measures is critical for the control of the outbreak, the reduction of related mortality and minimization of economic impact.

Purpose

To enable identification of key knowledge gaps, and research priorities and thereby accelerate the generation of critical scientific information and the most needed medical products to contribute to the control the 2019-nCoV emergency.

Expected outcome

A research roadmap with clearly defined priorities and governance framework addressing each of several thematic areas will be considered at the meeting, namely: virus, diagnostics; natural history and transmission; clinical; therapeutics; vaccines; ethics; regulatory science; animal health; data/samples analysis and sharing and; social sciences (<https://www.who.int/blueprint/en/>).

Attendees

The participants will include diverse multi-disciplinary teams:

- Member States representatives from countries with cases
- Representatives from the scientific community and public health agencies
- Regulatory experts
- Bioethicists with expertise in emergencies
- Major funders of research

WHO is delighted to welcome you to this 2.0 day in person meeting, which is organized in collaboration with GLOPID-R.



PROVISIONAL AGENDA

Day 1

Co-Chairs: Marie-Paule Kieny and Jeremy Farrar

Time	Sessions	Proposed Speaker/Moderators
SESSION 1: SETTING THE SCENE		
07:30	Registration	
09:00	Opening Remarks	Dr Tedros WHO Director General
09:15	Objectives of the meeting	Yazdan Yazdanpanah GLOPID R Chair
09:30	Overview of the outbreak situation and control measures being implemented	Michael J Ryan WHO
09:45	Epidemiological situation and current research efforts in China	Representative from China
10:00	Overview of R&D Blueprint efforts	R&D Blueprint co-leads
10:15	COFFEE BREAK	
10:45	BY THEMATIC AREA Overview of state of the art and outline of key knowledge gaps <ol style="list-style-type: none"> 1. Virus– natural history and transmission and diagnostics 2. Animal and environmental research on the virus origin, and management measures at the human-animal interface 3. Epidemiological studies 4. Clinical characterization and management 5. Infection prevention and control, including health care workers' protection 6. Therapeutics R&D 7. Candidate vaccine R&D 8. Ethical considerations for research 9. Integrating social sciences in the outbreak response 	<ol style="list-style-type: none"> 1. Christian Drosten/ Isabella Eckerle 2. Peter Daszak/ Sophie von Dobschuetz (TBC) 3. Gabriel Leung/ Silke Bude (TBC) 4. Bin Cao/Rob Fowler/ Yae Jan Kim (TBC) 5. John Conly/ Anna Levin (TBC) 6. Marco Cavaleri/ Ana Laura Salvati 7. Phil Krause/ Poonepalli Anuradha (TBC) 8. Ross Upshur/ Beatrice da Costa Thome 9. Nina Gobat/ Emily Chan (TBC)
13:30	LUNCH BREAK	



SESSION 2: DEFINING KNOWLEDGE GAPS, RESEARCH PRIORITIES AND A GOVERNANCE FRAMEWORK

14:30	<p>What are the knowledge gaps and the research priorities for this outbreak?</p> <p>How can the research stakeholders effectively coordinate their activities to ensure that gaps are addressed, and duplication is avoided (what governance framework could contribute to this?)</p> <ol style="list-style-type: none"> 1. Virus– natural history and transmission and diagnostics 2. Animal and environmental research on the virus origin, and management measures at the human-animal interface 3. Epidemiological studies 4. Clinical characterization and management 5. Infection prevention and control, including health care workers' protection 6. Therapeutics R&D 7. Candidate vaccine R&D 8. Ethical considerations for research 9. Social sciences in the outbreak response <p>Questions for clarification</p>	<p>CHAIRPERSONS</p> <ol style="list-style-type: none"> 1. Sophie van de Werf/ Isabella Eckerle 2. William Karesh/ Sophie von Dobschuetz (TBC) 3. Gabriel Leung/ Silke Bude (TBC) 4. John Marshall/ Srinivas Moorthy/ Yae Jan Kim (TBC) 5. Andreas Voss/Anna Levin (TBC) 6. Marco Cavaleri/ Ana Laura Salvati 7. Phil Krause/ Poonepalli Anuradha (TBC) 8. Ross Upshur/ Beatrice da Costa Thome 9. Lina Moses/ Emily Chan (TBC)
15:30	COFFEE BREAK	
15:30	<p>What are the knowledge gaps and the research priorities for this outbreak? (Continuation)</p>	Parallel sessions by thematic area
18:00	Adjourn	
18:30	COCKTAIL – RECEPTION	



Day 2

Chairperson: Nisia Lima and Chikwe Ihekweazu

Time	Sessions	Proposed Speaker/Moderator
SESSION 3: DEFINING KEY PRIORITIES AND OVERAL OBJECTIVES OF THE GLOBAL RESEARCH AGENDA		
08:30	BY THEMATIC AREA Feedback on the deliberations by thematic area by designated Rapporteurs <ol style="list-style-type: none"> 1. Virus– natural history and transmission and diagnostics 2. Animal and environmental research to understand role of animals and inform outbreak control 3. Epidemiological studies 4. Clinical characterization and management 5. Infection prevention and control, including health care workers' protection 6. Therapeutics R&D 7. Candidate vaccine R&D 8. Ethical considerations for research 9. Social sciences in the outbreak response 	Designated rapporteurs for each thematic area
11:00	COFFEE AND TEA	
11:30	Plenary discussion <ol style="list-style-type: none"> 1. What should be the overall objectives of a global research roadmap as a response to the current outbreak and in preparation for the future? 2. What are the most important actions to ensure successful evaluation and use (if appropriate) for any of the investigational interventions? 3. Available mechanisms for data and sample sharing. 	Plenary debate on the outcomes of the thematic groups led by the Chairpersons
13:00	LUNCH	
14:00	What governance model could contribute to the successful funding and implementation of the research agenda during this outbreak?	Panel discussion - Funders
15:30	COFFEE BREAK	



SESSION 4: CROSS-CUTTING RESEARCH ACTIVITIES

16:00	<p>Taking stock of deliberations and report back to Dr Tedros.</p> <ul style="list-style-type: none"> - Main knowledge gaps and research priorities - Model(s) of governance - Support required for success 	<p>Chairperson(s)</p> <p>J Farrar, MP Kieny, N Lima C. Ihekweazu</p>
17:00	Next steps: Summary by the WHO Secretariat	WHO
17:30	END OF THE MEETING	